News & Updates
Filter by Specialty:
Long-term aspirin use lowers HCC risk in chronic HBV patients
Use of aspirin in the long term appears to markedly reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV), a study has shown.
Long-term aspirin use lowers HCC risk in chronic HBV patients
14 May 2022
Oral silymarin reduces chemo-induced hepatotoxicity in breast cancer patients
Administration of oral silymarin leads to a substantial decrease in hepatotoxicity severity after 1 month of treatment in nonmetastatic breast cancer patients on doxorubicin/cyclophosphamide-paclitaxel (AC-T) regimen, reports a study.
Oral silymarin reduces chemo-induced hepatotoxicity in breast cancer patients
06 May 2022
Seladelpar safe, effective for primary biliary cholangitis
In patients with primary biliary cholangitis, the use of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, safely improves biochemical markers of cholestasis and inflammation, reports a new study.
Seladelpar safe, effective for primary biliary cholangitis
10 Apr 2022
Hepatitis B virus treatment rates still low among eligible patients
Administration rates of antiviral therapy remain low among treatment-eligible patients with chronic hepatitis B virus (CHB) and among CHB patients without human immunodeficiency virus (HIV), reveals a recent study.
Hepatitis B virus treatment rates still low among eligible patients
10 Apr 2022
Atezolizumab-bevacizumab combo trumps sorafenib for advanced HCC
The combination of atezolizumab and bevacizumab is better than sorafenib at maintaining clinically meaningful survival benefits over the long term in patients with unresectable hepatocellular carcinoma (HCC), reports a recent update to the IMbrave150 study.